
Analysis of Jazz Pharmaceuticals (JAZZ) options reveals potential yield-boosting strategies for investors. Selling the $100 strike price put offers a premium with a possible 11.10% return if it expires worthless, while selling the $120 strike price call against owned shares could yield 22.58% if the stock is called away; probabilities of these contracts expiring worthless are currently estimated at 69% and 46% respectively, with implied volatilities of 48% and 44%.
The article outlines two options strategies for Jazz Pharmaceuticals (JAZZ), currently trading at $109.32 per share. Selling a put contract at the $100.00 strike price, with a bid of $11.10, offers an investor a potential entry point at an effective cost basis of $88.90 per share if assigned. This strike represents an approximate 9% discount to the current share price. Analytical data suggests a 69% probability of this out-of-the-money put expiring worthless, which would result in an 11.10% return on the cash commitment, or an 11.78% annualized YieldBoost. Alternatively, for existing shareholders, selling a covered call at the $120.00 strike price, which has a bid of $14.00, could generate a total return of 22.58% if the stock is called away by the May 2026 expiration. This strike is approximately 10% above the current trading price. There's a 46% estimated probability of this call expiring worthless, in which case the premium would represent a 12.81% boost to returns (13.59% annualized). The implied volatility for the put is 48% and for the call is 44%, both notably higher than JAZZ's actual trailing twelve-month volatility of 35%, indicating that options premiums are currently elevated relative to recent historical price movements.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment